-

Allurion to Participate in the Jefferies Healthcare Conference

NATICK, Mass.--(BUSINESS WIRE)--Allurion, a company dedicated to ending obesity, today announced that it will be participating in the Jefferies Healthcare Conference taking place at the Marriott Marquis, New York, NY on June 7-9, 2023. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present on Friday, June 9, 2023 at 9:30 A.M. Eastern Time, and will be available for investor 1x1 meetings.

A webcast of the event will be available on the Allurion website.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight-loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.

The Allurion Program combines a 4-month swallowable gastric balloon with a 6-month behavior change and weight-loss program that is supported by a suite of digital tools that facilitate monitoring, coaching and telehealth. For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Contacts

Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com

Investor
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com

Industry:

Allurion

Release Summary
Allurion to Participate in the Jefferies Healthcare Conference
Release Versions
English

Contacts

Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com

Investor
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com

More News From Allurion

Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million in stockholders’ equity or (ii) at le...

Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Wa...

Allurion Receives U.S. FDA Approval

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule. “Today’s approval is a watershed moment for Allurion and for obesity care in the United States,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “Our goal is to deliv...
Back to Newsroom